Abstract
A series of chromone derivatives were designed as potential topoisomerase I (Top I) inhibitors based on the docking simulation study. Sixteen synthesized compounds were evaluated for Top I inhibitory activity and some compounds were further tested for in vitro cytotoxic activity. The most potent inhibitor, chromone 11b showed greater inhibitory activity (IC50 = 1.46 μM) than the known Top I inhibitors, i.e., camptothecin, fisetin and morin, but inactive against breast cancer cell (MCF-7), oral cavity cancer cell (KB) and small cell lung cancer (NCI-H187). Chromone 11c, another potent inhibitor (IC50 = 6.16 μM), exhibited cytotoxic activity against KB (IC50 = 73.32 μM) and NCI-H187 (IC50 = 36.79 μM).
Keywords: Chromone derivatives, topoisomerase I inhibitory activity, cytotoxic activity, enzymes, DNA, flavonoids, hydrogen bonds, melting points, dimethylsulfoxide, chromatography
Medicinal Chemistry
Title:Synthesis, Topoisomerase I Inhibitory and Cytotoxic Activities of Chromone Derivatives
Volume: 9 Issue: 3
Author(s): Chirattikan Maicheen, Jiraphun Jittikoon, Opa Vajragupta and Jiraporn Ungwitayatorn
Affiliation:
Keywords: Chromone derivatives, topoisomerase I inhibitory activity, cytotoxic activity, enzymes, DNA, flavonoids, hydrogen bonds, melting points, dimethylsulfoxide, chromatography
Abstract: A series of chromone derivatives were designed as potential topoisomerase I (Top I) inhibitors based on the docking simulation study. Sixteen synthesized compounds were evaluated for Top I inhibitory activity and some compounds were further tested for in vitro cytotoxic activity. The most potent inhibitor, chromone 11b showed greater inhibitory activity (IC50 = 1.46 μM) than the known Top I inhibitors, i.e., camptothecin, fisetin and morin, but inactive against breast cancer cell (MCF-7), oral cavity cancer cell (KB) and small cell lung cancer (NCI-H187). Chromone 11c, another potent inhibitor (IC50 = 6.16 μM), exhibited cytotoxic activity against KB (IC50 = 73.32 μM) and NCI-H187 (IC50 = 36.79 μM).
Export Options
About this article
Cite this article as:
Maicheen Chirattikan, Jittikoon Jiraphun, Vajragupta Opa and Ungwitayatorn Jiraporn, Synthesis, Topoisomerase I Inhibitory and Cytotoxic Activities of Chromone Derivatives, Medicinal Chemistry 2013; 9 (3) . https://dx.doi.org/10.2174/1573406411309030003
DOI https://dx.doi.org/10.2174/1573406411309030003 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
Call for Papers in Thematic Issues
Recent Advances in the Medicinal Chemistry of Cancer
Scope of the Thematic Issue: Correlation between structure and function is one of the important aspects of the success of anti-cancer compounds associated with their structure-activity interactions, physiology, biochemical, molecular, and genetic processes. Overcoming these obstacles is key to obtaining further insights into developments in rational drug design, bioorganic chemistry, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cytotoxic, Apoptotic and DNA Synthesis Inhibitory Effects of Some Thiazole Derivatives
Letters in Drug Design & Discovery N6-Isopentenyladenosine and its Analogue N6-Benzyladenosine Induce Cell Cycle Arrest and Apoptosis in Bladder Carcinoma T24 Cells
Anti-Cancer Agents in Medicinal Chemistry Diabetic Retinopathy: Current and New Treatment Options
Current Diabetes Reviews Development of a Lung Cancer Model in Wistar Rat and In Silico Screening of its Biomarkers
Current Computer-Aided Drug Design Long Noncoding RNA GAS5: A Novel Marker Involved in Glucocorticoid Response
Current Molecular Medicine Triggered Activation and Release of Liposomal Prodrugs and Drugs in Cancer Tissue by Secretory Phospholipase A2
Current Drug Delivery Cationic Liposomes as Non-viral Vector for RNA Delivery in Cancer Immunotherapy
Recent Patents on Drug Delivery & Formulation Current Nanotechnological Approaches for an Effective Delivery of Bioactive Drug Molecules to Overcome Drug Resistance Tuberculosis
Current Pharmaceutical Design A Review of Ground Glass Opacity Detection Methods in Lung CT Images
Current Medical Imaging Central Nervous System Abnormalities in Fibromyalgia and Chronic Fatigue Syndrome: New Concepts in Treatment
Current Pharmaceutical Design Semaphorins and their Receptors in Stem and Cancer Cells
Current Medicinal Chemistry Chronic Diseases and COVID-19: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Perspectives of Protein Kinase C (PKC) Inhibitors as Anti-Cancer Agents
Mini-Reviews in Medicinal Chemistry Indole Compounds Against Breast Cancer: Recent Developments
Current Drug Targets Expanding Targets for a Metabolic Therapy of Cancer: L-Asparaginase
Recent Patents on Anti-Cancer Drug Discovery The Emerging Role of Bcr-Abl-Induced Cystoskeletal Remodeling in Systemic Persistence of Leukemic Stem Cells
Current Drug Delivery Phosphoinositide 3-Kinases as Targets for Therapeutic Intervention
Current Pharmaceutical Design Synthesis and Investigation of the Role of Benzopyran Dihydropyrimidinone Hybrids in Cell Proliferation, Migration and Tumor Growth
Anti-Cancer Agents in Medicinal Chemistry Cancer Stem Cells: The ‘Achilles Heel’ of Chemo-Resistant Tumors
Recent Patents on Anti-Cancer Drug Discovery Patent Selections
Recent Patents on Anti-Cancer Drug Discovery